ad 32

Valrubicin (AD-32) (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity.

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.

Nurr1 Agonist 14 (Compound 32) is a Nurr1 agonist with an EC50 of 0.09 μM for Nurr1. It exhibits significant neuroprotective activity without being hindered by residual DHODH inhibition. This compound can upregulate neuroprotective genes in dopaminergic neurons, such as SOD2, SESN3, BIRC5, XIAP, FLRT2, and CRMP4. Nurr1 Agonist 14 is useful for studying neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS).

ARUK2010694 (Compound 20) is a potent and selective inhibitor of NUAK1, with a pIC50 value of 8.7. It also inhibits the activity of CDK2, CDK4, and CDK6, with inhibition rates of 13%, 63%, and 32% respectively at a concentration of 1 μM. ARUK2010694 is applicable in research on neurological disorders, including Alzheimer's disease (AD).

Valrubicin (Standard) is the standard substance of Valrubicin, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Valrubicin (AD-32) (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity.